CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged recently as one of the new standard treatments for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and several subtypes of B-cell non-Hodgkin lymphoma (NHL) (1–4). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.